IGM Biosciences stock has experienced a significant decline, indicating an overall bearish sentiment in the market. The company's high expenses and poor financial management have devalued the company.

The iShares Expanded Tech Sector ETF (NYSEARCA:IGM) is a comprehensive ETF that gives investors exposure to the full spectrum of the North American tech sector, as it includes key tech-related stocks ...

Researchers at UMC Utrecht have discovered that converting monoclonal antibodies from the IgG to the IgM isotype can ...

Higher interest rates and worries about banking system stability and a recession have rocked the market and caused the energy and financial Sectors to sell off. Surprisingly enough to some investors, ...

4 analysts have expressed a variety of opinions on IGM Biosciences (NASDAQ:IGMS) over the past quarter, offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments ...

HC Wainwright & Co. downgraded its rating of IGM Biosciences (NASDAQ:IGMS) to Neutral with a price target of $7.00, changing its price target from $11.00 to $7.00. Shares of IGM Biosciences are ...

IGM's combination of the in-house investment management groups from Mackenzie and Investors Group into a single shop (housed under the Mackenzie Investments brand) has enhanced the scale of the firm's ...

Detailed price information for Igm Financial Inc (IGIFF) from The Globe and Mail including charting and trades.

Nesto is principally backed by Portage Ventures, IGM Financial with additional backing from Diagram Ventures, NAventures, BMO Capital Partners and others.

Objective Glomerular immune complex deposition plays a central role in lupus nephritis (LN), but the prognostic relevance of individual immunoglobulin components remains unclear. This study aimed to ...

Thinking about whether to buy, hold, or part ways with IGM Financial? You are not alone. This stock has prompted plenty of second looks, especially after its robust run. Just over the past week, ...